

Special Issue

In-Depth Exploration of Immuno-Oncology and Engineering Immune Cells to Kill Cancer Cells

Message from the Guest Editors

Immune system protects the body from infection and disease. Cancer is a kind of disease that outsmarts the body's immune system and evades its defenses. In most cases, it doesn't show up until it is too late to do anything about it. In recent years, advances in cancer immunotherapy have improved immune system's ability to fight cancer. Despite this, it has some complications and uncertainty, as it can destroy healthy cells. Due to recent developments in targeted immunotherapy, adverse effects of cellular immunotherapy may be reduced, and patient survival might be improved. This special issue will publish original research articles and reviews demonstrating the impact of targeted specific engineered immune cells (Bispecific, BITE, Engagers) in the clinical management of hematologic malignancies.

Guest Editors

Dr. Anudishi Tyagi

MD Anderson Cancer Center, University of Texas, Houston, TX, USA

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Deadline for manuscript submissions

closed (27 March 2024)



Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



mdpi.com/si/134152

Hematology Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
hematolrep@mdpi.com

[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)





Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.2
CiteScore 1.4
Indexed in PubMed



[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)



About the Journal

Message from the Editor-in-Chief

Hematology Reports (ISSN 2038-8330) is an international open access journal on all aspects of prevention, diagnosis and management of disorders of the blood, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology and controlled trials.

Editor-in-Chief

Dr. Claudio Cerchione
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014
Meldola, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 26.9 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).